Thought control: AI model transcribes thoughts from brainwaves
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Elation Survey Finds Nearly 40% of Primary Care Physicians Use AI-powered Tools for Daily Clinical Documentation
SAN FRANCISCO--(BUSINESS WIRE)-- Elation Health, the clinical-first technology company powering innovation in primary care, today announced the results of its latest AI in Primary Care survey of 291 primary care physicians, focused on the current sentiments, adoption patterns, critical concerns (defects), key behavioral insights (learnings), and explicit user desires (requests) regarding the integration of Artificial Intelligence (AI) in primary care workflows. The analysis reveals 39.3% use AI-powered tools daily, specifically for clinical documentation. The survey also revealed that clinicians have a clear hierarchy of needs when it comes to AI, with fundamental performance factors at the top of that hierarchy. With 59% of respondents in agreement, accuracy and reliability ranked as the most important factor when evaluating AI tools. Seamless workflow integration and ease of use followed at 22%, while efficiency and time savings (ROI) came in at 13%, and cost affordability at 6% (see Table 1). Table 1: Most Important Factors in Choosing an AI Tool 'Our survey confirms what we already suspected: clinicians are cautiously optimistic about AI's potential, but they're looking for thoughtful, trustworthy, affordable solutions that truly fit the realities of primary care,' said Sara Pastoor, MD, MHA, FAAFP, and director of primary care advancement for Elation Health. 'At Elation, we're applying AI in ways that are context-aware, and fit naturally into clinical and operational workflows to enable high-quality care hand in hand with long-term financial success.' While the survey also affirmed the general attitude towards AI in clinical settings is predominantly positive, a notable segment remains neutral or skeptical. Although a combined 59% of respondents rate their sentiment as "Positive" or "Very Positive," 24% of respondents were 'Neutral' in their sentiments about AI. This sizable group appears to be open to AI advancements but may be likely waiting for clear evidence of its value, reliability, and ease of use before fully embracing it. These findings reinforce how Elation approaches research and development with Elation's Innovation Labs that leverage a dynamic, interactive product development and testing framework to allow it to work shoulder-to-shoulder with clinicians and staff through design cycles, usability testing, and continuous in-product feedback. This ensures Elation is developing AI in ways that clinicians trust and find valuable. Elation Health's clinical-first approach to AI is distinguished by continuous, hands-on collaboration with primary care clinicians throughout the Elation Labs development process. Every new AI capability is shaped directly by clinician feedback, gathered through design cycles, usability testing, and ongoing in-product input. Elation's iterative, transparent partnership with customers ensures that its AI features are clinically relevant, trustworthy, and seamlessly integrated into daily workflows, empowering clinicians while keeping the focus firmly on patient care. The survey was conducted with 291 independent primary care clinicians who are current Elation Health customers. For more on the results from Elation's State of AI in Primary Care Clinical Practice survey, visit here. To join Elation's product developers for a live, interactive webinar to explore how ethical, clinician-designed AI embedded within the EHR is transforming primary care by reducing burnout, improving care quality, and empowering both clinicians and patients: register here. About Elation Elation Health is the clinical-first AI platform for primary care success. Trusted by over 36,000 clinicians and 20 million patients, Elation's EHR and billing solutions combine proven clinical workflows with responsible, predictive AI - purpose built for primary care. The company's clinical-first approach puts physicians at the center, delivering trusted, transparent innovation that saves time and sustains meaningful patient relationships. Elation Health is recognized as Best in KLAS for its commitment to excellence in primary care technology. Learn more at and on LinkedIn.
Yahoo
2 hours ago
- Yahoo
Life might have come from outer space, scientist say
The seeds of life on Earth might have come from outer space – and might be widespread throughout the rest of the universe, scientist say. Researchers have found complex organic molecules in a disc around a 'protostar' in a major breakthrough. Those molecules are seen as the precursors to the building blocks of life, which go on to become sugars and amino acids that are then combined into the complex flora and fauna that surrounds us. Researchers have found such complex organic molecules in other places before. But the new findings fill in a previously mysterious missing link – one that could suggest that life is more abundant than we realise. When cold protostar becomes a young star, surrounded by a disc of dust and gas, it is a violent process that includes intense radiation and the hurling out of gas. Researchers had been concerned that the extreme nature of that process could 'reset' the chemical compounds available around a star, meaning that they would have to be formed in the discs that at the same time are making planets. But the new findings suggest that complex molecules can stick around through that process, meaning they will be inherited by the discs that follow. The findings are reported in a new study, 'A deep search for Complex Organic Molecules toward the protoplanetary disk of V883 Ori', published in the The Astrophysical Journal Letters.
Yahoo
3 hours ago
- Yahoo
The Figma IPO Is Coming -- but Can It Justify Its Valuation?
Key Points IPOs have been hot this year, with most of the big ones generating strong returns in just a few months. Figma makes building design and user interface projects much more collaborative, and it plans to integrate many artificial intelligence tools. The company is targeting a valuation in the range of $13.6 billion to $16.5 billion fully diluted. These 10 stocks could mint the next wave of millionaires › Investors who have participated in initial public offerings (IPOs) like CoreWeave, Circle Internet Group, and Chime Financial have done quite well this year, which is why it's no surprise to see big hype around another incoming IPO, Figma. Positioned as the Google Sheets of the design and user interface world, Figma allows multiple people to collaborate on design projects, although the company has really morphed into a way for companies to turn ideas into software. Figma sees immense potential to integrate artificial intelligence into its business and even owns crypto as well. Figma is planning to IPO at a valuation in the range of $13.6 billion to $16.5 billion on a fully diluted basis. But does the company's exciting business justify this large valuation? A real game changer in design Brown University alums Dylan Field and Evan Wallace launched Figma in 2012, seeking a way to make the design process more collaborative from a technological perspective. They would eventually create a platform that allowed multiple people to work on design projects through the power of the web but also with high-quality graphics. Image source: Getty Images. As technology advanced, the platform did as well, particularly with the release of Dev Mode in 2023, which allowed designers to translate their concepts into code without changing the design file. This ultimately made it easier for designers and coders to work together. Products like this have gained traction, and today, Figma has 13 million unique monthly users, two-thirds of whom aren't designers. Roughly 95% of companies in the Fortune 500 use Figma, so the company is not reliant on a few core customers. Additionally, Figma sees immense potential to integrate more artificial intelligence (AI) tools into its business. Figma Make already lets users convert a conversational prompt into a working prototype in just minutes. The company believes it stands to benefit from the growth of AI, projecting that there will be 1 billion new apps in the world by 2028, many of which will come to Figma for their branding and user interface. Do the financials justify the valuation? The big question with all of these new and exciting IPOs is: Are they too hot out of the gate, or can their growth really justify the valuation? Figma is looking to raise $1 billion and list shares at $25 to $28, giving it a valuation of $13.6 billion at the high end of that range. However, Barron's estimates that the valuation could really be as high as $16.5 billion on a fully diluted basis.
